Program
laroprovstat
Also written as “AZD0780”, “FDC laroprovstat/Rosuvastatin 1” and “FDC laroprovstat/Rosuvastatin 2”.
Its studies are mostly in Dyslipidemias · Hypercholesterolemia · Cardiovascular Diseases · Hyperlipidemias · Atherosclerosis, led by AstraZeneca.
Drug pageLaroprovstat: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 227 open or running | phase 3since Dec 2, 2024 | May 17, 2022 | Jan 4, 2027phase 3 · NCT07000136 |
- Named in AstraZeneca’s own pipeline as
laroprovstat
, phase 3, as of Oct 30, 2026 (source).
Also a collaborator on its studies: Parexel, Fortrea and Quotient Sciences.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 6 studies since May 17, 2022.
- Aug 11, 2024Named laroprovstatINNProposed as its International Nonproprietary Name in WHO's List 131 · before, AZD0780
- Sep 23, 2024Phase 1 study in DyslipidemiasNCT06671405 · 59 enrolled · United States
- Oct 28, 2024Phase 2 study in AtherosclerosisNCT06692764 · 202 enrolled · United States
- Dec 2, 2024Phase 3 study in DyslipidemiasNCT06834932 · 432 enrolled · China, Hong Kong
- Dec 16, 2024Phase 1 study in DyslipidemiasNCT06742853 · 81 enrolled · United States, United Kingdom
- May 23, 20253 phase 3 studiesNCT07000136, NCT07000123, NCT07000357
- Oct 10, 2025Phase 1 study in DyslipidemiasNCT07216131 · 14 enrolled · United States
- Oct 17, 2025Phase 2 study in DyslipidemiasNCT07218900 · 76 enrolled · Russia
- Dec 19, 2025Phase 1 study in HyperlipidemiasNCT07316608 · 44 enrolled · United States
- Feb 13, 2026Phase 1 study in DyslipidemiasNCT07423598 · 40 enrolled · United States
- Mar 31, 2026Phase 1 study in DyslipidemiasNCT07513571 · 31 enrolled · United States
- May 26, 20262 phase 3 studies in HypercholesterolemiaNCT07619131, NCT07619118
- May 28, 2026Phase 1 study in HyperlipidemiasNCT07622433 · 18 enrolled · United States
- Nov 5, 2026Phase 3 study in HypercholesterolemiaNCT07930507 · 204 planned · China, Hong Kong, Malaysia and more
- Nov 13, 2026Primary completion moved from 2025-07-03 to 2027-02-22Date moved laterphase 3 · +20 months · NCT06834932
Ahead
- Jan 4, 2027Primary completion: phase 3 study in Heterozygous Familial HypercholesterolaemiaNCT07000136
- Jan 11, 2027Primary completion: phase 3 study in Cardiovascular DiseasesNCT07000123
- Feb 22, 2027Primary completion: phase 3 study in DyslipidemiasNCT06834932
- May 28, 2027Primary completion: phase 3 study in HypercholesterolemiaNCT07619118
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 22 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07930507Hypercholesterolemia · China, Hong Kong, Malaysia and more | 3 | Not yet recruiting | Oct 11, 2027 | 204 |
| NCT07622433Hyperlipidemias · United States | 1 | Completed | Sep 6, 2026 | 18 |
| NCT07619131Hypercholesterolemia · United States, Bulgaria, Canada and more | 3 | Recruiting | Jul 30, 2027 | 600 |
| NCT07619118Hypercholesterolemia · United States, Australia, Canada and more | 3 | Recruiting | May 28, 2027 | 200 |
| NCT07513571Dyslipidemias · United States | 1 | Completed | Jul 8, 2026 | 31 |
| NCT07423598Dyslipidemias · United States | 1 | Completed | Jun 29, 2026 | 40 |
| NCT07316608Hyperlipidemias · United States | 1 | Completed | Jun 5, 2026 | 44 |
| NCT07218900Dyslipidemias · Russia | 2 | Completed | Sep 3, 2026 | 76 |
| NCT07216131Dyslipidemias · United States | 1 | Completed | Dec 30, 2025 | 14 |
| NCT07000357Cardiovascular Diseases · United States, Argentina, Brazil and more | 3 | Recruiting | Oct 26, 2029 | 15,100 |
| NCT07000136Heterozygous Familial Hypercholesterolaemia · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jan 4, 2027 | 473 |
| NCT07000123Cardiovascular Diseases · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jan 11, 2027 | 3,103 |
| NCT06742853Dyslipidemias · United States, United Kingdom | 1 | Completed | Oct 29, 2025 | 81 |
| NCT06834932Dyslipidemias · China, Hong Kong | 3 | Active, not recruiting | Feb 22, 2027 | 432 |
| NCT06692764Atherosclerosis · United States | 2 | Completed | Apr 18, 2025 | 202 |
| NCT06671405Dyslipidemias · United States | 1 | Completed | Feb 17, 2025 | 59 |
| NCT06576765Hepatic Impairment · United States | 1 | Completed | Nov 8, 2024 | 16 |
| NCT06592482Renal Insufficiency · United States | 1 | Completed | Dec 1, 2024 | 30 |
| NCT06173570Dyslipidemias · United States, Canada, Czechia and more | 2 | Completed | Sep 30, 2024 | 428 |
| NCT05817461Cardiovascular Diseases · United Kingdom | 1 | Completed | Jun 6, 2023 | 8 |
| NCT05787002Dyslipidemias · United States | 1 | Completed | May 15, 2023 | 16 |
| NCT05384262Dyslipidemias · United States, United Kingdom | 1 | Completed | Jun 14, 2024 | 183 |
How it is read
Names in the registry
- “AZD0780”, 17 entries
- “FDC laroprovstat/Rosuvastatin 1”, 1 entry
- “FDC laroprovstat/Rosuvastatin 2”, 1 entry
- “laroprovstat/rosuvastatin 1”, 1 entry
- “laroprovstat/rosuvastatin 2”, 1 entry
Conditions, from the studies’ own filings
- Dyslipidemias, 10 studies
- Hypercholesterolemia, 3 studies
- Cardiovascular Diseases, 3 studies
- Hyperlipidemias, 2 studies
- Atherosclerosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.